1 / 33

Diabetes Care in Turkey

Diabetes Care in Turkey. Prof. Dr. Taner Damcı Istanbul University Cerrahpaşa Medical Faculty Department on Endocrinology Metabolism and Diabetes. TURDEP Diabetes prevalence in Turkey due to ages. P<0.0001. Satman İ, TURDEP Group . D iabetes Care 2002 ; 25: 1551-6. TURDEP

devaki
Download Presentation

Diabetes Care in Turkey

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Care in Turkey Prof. Dr. Taner Damcı Istanbul University Cerrahpaşa Medical Faculty Department on Endocrinology Metabolism and Diabetes

  2. TURDEP Diabetes prevalence in Turkey due to ages P<0.0001 Satman İ, TURDEP Group. Diabetes Care 2002; 25: 1551-6

  3. TURDEP Prevalence of IGT in Turkey due to ages P<0.0001 Satman İ, TURDEP Group. Diabetes Care 2002; 25: 1551-6

  4. Diabetes prevalence in Turkey due to age and gender Satman İ, TURDEP Group. Diabetes Care 2002; 25: 1551-6

  5. P<0.0001 BMI30 kg/m2 Satman I, Yilmaz MT, and the TURDEP Group. Diabetologia 2000; 43:433, A111

  6. Prevalence of Obesity in Turkey TURDEP Çalışması

  7. Results of the Turkish Obesity and Metabolic Syndrome Survey TEMD Türkiye Metabolik Sendrom Taraması - Prof. Dr. Fahri BAYRAM

  8. Results of the Turkish Obesity and Metabolic Syndrome Survey

  9. Prevalence in obese children and adolescents. AGH: abnormal glucose homoeostasis, IR: insulin resistance, IGT: impaired glucose tolerance, IFG: impaired fasting glucose, HI: hyperinsulinemia, DL: dyslipidaemia, HT: hypertension, DM: type 2 diabetes, MS: metabolic syndrome. Diabetes Research and Clinical PracticeVolume 72, Issue 3, June 2006, Pages 315-321

  10. Baseline characteristics (FAS) Patients demographics

  11. BMI- Type 1 Male N=93 Female N=94 < 20 20-25 25-30 30-35 >35

  12. BMI- Type 2 Male N=428 Female N=494 < 20 20-25 25-30 30-35 >35

  13. Diabetes late complications

  14. Other cardiovascular risk factors

  15. Patients antidiabetic treatments

  16. Oral Hypoglycemic Agents

  17. Insulin treatment : Type of insulin Type 1 N=186 Type 2 N=277 Basal Bas + Prand Prandial alone Premix Others

  18. Insulin treatment : Number of injections per day Type 1 N=186 Type 2 N=277 > 3 /day 1/day 2/day 3/day

  19. Glycemic control

  20. Frequency of monitoring of glycemic control in the whole population

  21. Frequency of monitoring of glycemic control whole population (by class)

  22. Reasons for not achieving target – Type 1 N=130 % of answers Concom. illness Fear of injections Weight concern Hypo

  23. Reasons for not achieving target – Type 2 Type 2 without insulin N=374 % Weight concern Concom. illness Fear of injections Hypo Type 2 insulin treated N=197 Hypo Weight concern Concom. illness Fear of injectons

  24. Patient education and follow up

  25. Absenteeism and hospitalisation due to diabetes

  26. Predictive factors of « reaching target » • Variables evaluated for T1DM • Age • BMI • Time since diagnosis • SMBG • Training by a diabetes educator • Frequency of consultations • Self adjustment of insulin • Factors evaluated for T2DM • Age • BMI • Time since diagnosis • SMBG • Training by a diabetes educator • Frequency of consultations • Self adjustment of insulin • Number of OADs

  27. SUB-OPTIMAL DRUG TREATMENT OF DIABETES AND CARDIOVASCULAR RISK IN DIABETIC PATIENTS IN TURKEY; A COUNTRYWIDE SURVEY Taner DAMCI Hakan KULTURSAY Aytekin OGUZ Seckin PEHLIVANOGLU Lale TOKGOZOGLU, (The Vascular Risk Study Group) Diabetes and Metabolism

  28. Antidiabetic drug choice

  29. Antihypertensives %

  30. No of antihypertensives % Antihipertansifilaç sayısı

  31. Drug use in microalbuminuric patients % 31 % 58 % 11

  32. Statin % 19 Kolesterol > 200 mg/dl % 32 Fibratlar % 1 Aspirin % 30 Daha önce KV olay geçiren diabetiklerde % 54

  33. Conclusions • Diabetes is prevalent as are the complications of the disease in Turkey • Care of diabetic patients is not optimal • This is probably due to educational, economic, time constraints

More Related